These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15711991)

  • 21. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy.
    Yeh YT; Peng JH; Peng HP
    J Cosmet Dermatol; 2018 Oct; 17(5):675-687. PubMed ID: 30091170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intramuscular nerve distribution of the masseter muscle as a basis for botulinum toxin injection.
    Kim DH; Hong HS; Won SY; Kim HJ; Hu KS; Choi JH; Kim HJ
    J Craniofac Surg; 2010 Mar; 21(2):588-91. PubMed ID: 20489458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report.
    Mandel L; Tharakan M
    J Oral Maxillofac Surg; 1999 Aug; 57(8):1017-9. PubMed ID: 10437733
    [No Abstract]   [Full Text] [Related]  

  • 24. Botulinum toxin treatment of bilateral masseteric hypertrophy.
    Smyth AG
    Br J Oral Maxillofac Surg; 1994 Feb; 32(1):29-33. PubMed ID: 8136335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle.
    Kim NH; Park RH; Park JB
    Plast Reconstr Surg; 2010 Jun; 125(6):1693-1705. PubMed ID: 20517093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle.
    Kim JH; Shin JH; Kim ST; Kim CY
    Plast Reconstr Surg; 2007 Feb; 119(2):711-7. PubMed ID: 17230111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment.
    Xie Y; Zhou J; Li H; Cheng C; Herrler T; Li Q
    Plast Reconstr Surg; 2014 Aug; 134(2):209e-218e. PubMed ID: 25068343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Lee SH; Wee SH; Kim HJ; Yeo UC; Lee NH; Lee SW; Cho SB
    J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complications of botulinum toxin injection for masseter hypertrophy: Incidence rate from 2036 treatments and summary of causes and preventions.
    Peng HP; Peng JH
    J Cosmet Dermatol; 2018 Feb; 17(1):33-38. PubMed ID: 29250900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy.
    Lee SK
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S105-10. PubMed ID: 17278332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum Toxin Injections for Masseter Reduction in East Asians.
    Cheng J; Hsu SH; McGee JS
    Dermatol Surg; 2019 Apr; 45(4):566-572. PubMed ID: 30883483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anatomical Considerations When Treating Compensatory Hypertrophy of the Upper Part of the Masseter after Long-Term Botulinum Neurotoxin Type A Injections.
    Lee KL; Cho HJ; Bae H; Park HJ; Park MS; Kim HJ
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32235784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin for masseter reduction in Asian patients.
    Ahn J; Horn C; Blitzer A
    Arch Facial Plast Surg; 2004; 6(3):188-91. PubMed ID: 15148129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Botulinum Toxin in Treating Asian Indian Patients with Masseter Hypertrophy: A 4-Year Follow-Up Study.
    Shome D; Khare S; Kapoor R
    Plast Reconstr Surg; 2019 Sep; 144(3):390e-396e. PubMed ID: 31461011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects.
    Quezada-Gaon N; Wortsman X; Peñaloza O; Carrasco JE
    J Cosmet Dermatol; 2016 Sep; 15(3):238-44. PubMed ID: 26799545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between Conventional Blind Injections and Ultrasound-Guided Injections of Botulinum Toxin Type A into the Masseter: A Clinical Trial.
    Bae H; Kim J; Seo KK; Hu KS; Kim ST; Kim HJ
    Toxins (Basel); 2020 Sep; 12(9):. PubMed ID: 32932891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commentary: The effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Ahn KY
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2167. PubMed ID: 21244566
    [No Abstract]   [Full Text] [Related]  

  • 38. [The use of botulinum toxin type A in masseter muscle hypertrophy: long-term effects and lasting improvement].
    Aydil B; Başaran B; Unsaler S; Süoğlu Y
    Kulak Burun Bogaz Ihtis Derg; 2012; 22(5):249-53. PubMed ID: 22991984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrasonographic Considerations for Safe and Efficient Botulinum Neurotoxin Injection in Masseteric Hypertrophy.
    Lee HJ; Jung SJ; Kim ST; Kim HJ
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33406757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome.
    Jordan SE; Ahn SS; Freischlag JA; Gelabert HA; Machleder HI
    Ann Vasc Surg; 2000 Jul; 14(4):365-9. PubMed ID: 10943789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.